Medicine
Kaletra 200 mg/50 mg tablet
Kaletra 200 mg/50 mg tablet is a prescription medicine containing Lopinavir and Ritonavir for oral use, marketed by AbbVie, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Oral Solution Store KALETRA oral solution at 2°- 8°C (36°- 46°F) until…
Key facts
- Active ingredient (INN)
- Lopinavir and Ritonavir
- Brand
- Kaletra
- Strength
- 200 mg/50 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 120 tablets
- Marketing authorisation holder
- AbbVie
- Manufacturer
- AbbVie
- Origin register
- US FDA, United States
- Storage
- Oral Solution Store KALETRA oral solution at 2°- 8°C (36°- 46°F) until dispensed. For patient use: refrigerated KALETRA oral solution remains stable until the expiration date printed on the label. Store KALETRA tablets at 20°- 25°C (68°- 77°F), excursions permitted to 15°- 30°C (59°- 86°F). If stored at room temperature up to 25°C (77°F), oral solution should be used within 2 months.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AR10 Lopinavir and Ritonavir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 8 April 2020
- Identifiers
- RxCUI 311369, 597730, 746645 +3DailyMed set ID 8290add3-4449-4e58-6c97-8fe1eec972e3NDC 0074-4014Application NDA021906
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 120 tablet, film coated in 1 bottle | 0074-4014-12 | AbbVie | 15 February 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Lopinavir and Ritonavir 200 mg/50 mg tablet.
Other strengths and forms of Lopinavir and Ritonavir
Clinical summary
Lopinavir and Ritonavir is a fixed-dose combination of a protease inhibitor and a cytochrome P450 3A inhibitor. It is available as tablets and oral solution. MedsAcross supplies Lopinavir and Ritonavir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Lopinavir and RitonavirFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Kaletra prescribing information (AbbVie) · U.S. National Library of Medicine, DailyMed
- Kaletra: European public assessment report (EPAR) · European Medicines Agency
- Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan): European public assessment report (EPAR) · European Medicines Agency
Need Kaletra 200 mg/50 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.